<DOC>
	<DOCNO>NCT00728585</DOCNO>
	<brief_summary>RATIONALE : Palifermin may help relieve prevent oral mucositis cause chemotherapy radiation therapy young patient undergoing stem cell transplant . PURPOSE : This randomized phase II trial study palifermin see well work compare placebo prevent oral mucositis cause chemotherapy and/or radiation therapy young patient undergoing stem cell transplant .</brief_summary>
	<brief_title>Palifermin Preventing Oral Mucositis Caused Chemotherapy and/or Radiation Therapy Young Patients Undergoing Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare whether palifermin versus placebo administer pediatric patient three day prior condition three day autologous allogeneic hematopoietic stem cell transplantation ( HSCT ) associate reduction incidence WHO grade 3 4 oral mucositis . Secondary - To evaluate safety tolerability palifermin . - To evaluate long-term effect palifermin disease outcome survival . - To compare incidence , total dose , duration parenteral opioid analgesic use ( morphine equivalent ) , incidence duration total parenteral nutrition ( TPN ) administration patient treat regimen . - To compare incidence febrile neutropenia invasive bacterial infection patient treat regimen . - To determine whether palifermin versus placebo reduces incidence WHO grade 3 4 oral mucositis among allogeneic HSCT pediatric patient receive methotrexate graft-versus-host disease ( GVHD ) prophylaxis . - To determine whether palifermin versus placebo reduces acute chronic GVHD allogeneic HSCT . - To describe health care utilization ( hospitalization duration , administration antibiotic , TPN , nasogastric- , nasojejunal- gastrostomy-administered enteral nutrition , blood product ) pediatric patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord age year ( 1 2 v 3 11 v 12 16 ) , type hematopoietic stem cell transplantation ( HSCT ) ( autologous v allogeneic ) , condition regimen ( either total-body irradiation [ TBI ] melphalan v neither TBI melphalan ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive palifermin IV daily 3 day prior chemotherapy and/or radiotherapy absence unacceptable toxicity . Patients receive palifermin IV day 0 , 1 , 2 autologous allogeneic HSCT . - Arm II : Patients receive placebo IV daily 3 day prior chemotherapy and/or radiotherapy absence unacceptable toxicity . Patients receive placebo IV day 0 , 1 , 2 autologous allogeneic HSCT . Blood sample collect baseline , 32 day , 100 day HSCT evaluate immunogenicity palifermin . Oral mucositis assess baseline , daily 8 day prior 32 day HSCT , oral mucositis resolve WHO Mucositis Scale , Oral Mucositis Assessment Scale ( OMAS ) , modify Walsh mucositis scale , Oral Mucositis Daily Questionnaire ( OMDQ ) , pain categorical rating scale . After completion HSCT , patient follow periodically 10 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients undergo myeloablative autologous allogeneic hematopoietic stem cell transplantation ( HSCT ) indication Any type myeloablative HSCT condition regimen allow Patients undergo allogeneic HSCT may undergo 1 follow type donor stem cell : HLAmatched sibling parent Partially match family donor ( mismatch single HLA locus [ class I ] ) Fully match unrelated marrow peripheral blood stem cell donor HLAmatched partially mismatch ( least 4 6 match ) cord blood ( class I II ) PATIENT CHARACTERISTICS : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No HIV positivity No known sensitivity E. coliderived product Known grade 1 2 allergic reaction asparaginase allow No prior grade 34 allergy asparaginase pegaspargase PRIOR CONCURRENT THERAPY : See Disease Characteristics More 30 day since prior concurrent treatment follow therapy : Oral cryotherapy Glutamine oral supplement Traumeel® Gelclair® Oral vancomycin paste Lowlevel laser therapy An investigational product device another clinical trial No prior palifermin keratinocyte growth factor No concurrent cytotoxic drug condition graftvshost disease prophylaxis Intrathecal methotrexate cytarabine CNS involvement allow</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>mucositis</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent Wilms tumor childhood kidney tumor</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>